AR040343A1 - Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age - Google Patents
Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con ageInfo
- Publication number
- AR040343A1 AR040343A1 ARP030102293A AR040343A1 AR 040343 A1 AR040343 A1 AR 040343A1 AR P030102293 A ARP030102293 A AR P030102293A AR 040343 A1 AR040343 A1 AR 040343A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- diabetic
- treatment
- prophylaxis
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 5
- 208000030159 metabolic disease Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 8
- 206010012601 diabetes mellitus Diseases 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 238000011321 prophylaxis Methods 0.000 abstract 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 208000017169 kidney disease Diseases 0.000 abstract 3
- 108010005094 Advanced Glycation End Products Proteins 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 2
- 206010048554 Endothelial dysfunction Diseases 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 2
- 230000008694 endothelial dysfunction Effects 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010027525 Microalbuminuria Diseases 0.000 abstract 1
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 206010061989 glomerulosclerosis Diseases 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000001631 hypertensive effect Effects 0.000 abstract 1
- -1 methylenedioxy ring Chemical group 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 201000009925 nephrosclerosis Diseases 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de inhibidores de vasopeptidasa de la fórmula (1) para el tratamiento y/o profilaxis de nefropatía en pacientes diabéticos o no diabéticos, incluida la nefropatía diabética o no diabética, glomerulonefritis, esclerosis glomerular, síndrome nefrótico, nefroesclerosis hipertensiva, microalbuminuria o enfermedad renal de fase terminal, o resistencia a la insulina o de enfermedades metabólicas asociadas con productos finales de glicación avanzada tales como complicaciones diabéticas, neuropatía diabética, nefropatía diabética, retinopatía diabética, cataratas, infarto de miocardio y/o cariomiopatía diabética, o aterosclerosis o disfunción endotelial. Reivindicación 1: Uso de un compuesto de fórmula (1) en donde: A = H, alquilo C1-8, CH2OCH2CH2OCH3, -(alquilo C1-4).-arilo; R1 es hidrógeno, -CH2OC(O)C(CH3)3, o un grupo acilo; R2 es hidrógeno, -CH2O-C(O)C(CH3)3; un alquilo C1-4; arilo, -(alquil C1-4)-arilo; o difenilmetilo; X es -(CH2)n, en donde n es un número entero 0 ó 1, -S-, -O-, o un resto seleccionado del grupo de fórmulas (2), en donde R3 es hidrógeno, un alquilo C1-4, arilo o aril-(alquilo C1-4), y R4 es -CF3, alquilo C1-10, arilo o aril-(alquilo C1-4); B1 y B2, cada uno independientemente, son hidrógeno, hidroxi, -OR5, en donde R5 es alquilo C1-4, arilo o -(alquil C1-4)-arilo, o en los casos en que B1 y B2 estén unidos a átomos de carbono adyacente, B1 y B2 pueden ser tomados juntos con dichos átomos de carbono adyacentes para formar un anillo de benceno o metilendioxi, para el tratamiento y/o profilaxis de nefropatía en pacientes no diabéticos, para el tratamiento y/o profilaxis de resistencia a insulina o enfermedades metabólicas asociadas con productos finales de glicación avanzada, o para el tratamiento y/o profilaxis de aterosclerosis y disfunción endotelial.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2002129180 DE10229180A1 (de) | 2002-06-28 | 2002-06-28 | Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040343A1 true AR040343A1 (es) | 2005-03-30 |
Family
ID=29795983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030102293 AR040343A1 (es) | 2002-06-28 | 2003-06-26 | Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US6930103B2 (es) |
| EP (1) | EP1519732B1 (es) |
| JP (1) | JP4564354B2 (es) |
| KR (1) | KR101072235B1 (es) |
| CN (1) | CN100366254C (es) |
| AR (1) | AR040343A1 (es) |
| AT (1) | ATE548040T1 (es) |
| AU (1) | AU2003280440B2 (es) |
| BR (1) | BR0312250A (es) |
| CA (1) | CA2490277C (es) |
| CR (1) | CR7667A (es) |
| CY (1) | CY1112905T1 (es) |
| DE (1) | DE10229180A1 (es) |
| DK (1) | DK1519732T3 (es) |
| EC (1) | ECSP045513A (es) |
| ES (1) | ES2383889T3 (es) |
| HN (1) | HN2003000193A (es) |
| HR (1) | HRP20041212B1 (es) |
| IL (2) | IL165935A0 (es) |
| MA (1) | MA27281A1 (es) |
| MX (1) | MXPA04012230A (es) |
| NO (1) | NO334811B1 (es) |
| NZ (1) | NZ537480A (es) |
| OA (1) | OA12871A (es) |
| PA (1) | PA8576501A1 (es) |
| PE (1) | PE20040582A1 (es) |
| PL (1) | PL218070B1 (es) |
| PT (1) | PT1519732E (es) |
| RS (1) | RS52478B (es) |
| RU (1) | RU2336080C2 (es) |
| SI (1) | SI1519732T1 (es) |
| SV (1) | SV2004001560A (es) |
| TN (1) | TNSN04262A1 (es) |
| TW (1) | TWI326215B (es) |
| UA (1) | UA82845C2 (es) |
| UY (1) | UY27869A1 (es) |
| WO (1) | WO2004002492A1 (es) |
| ZA (1) | ZA200409382B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2482546C2 (ru) * | 2011-04-28 | 2013-05-20 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к с-концевому фрагменту рецептора ангиотензина ii |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5430145A (en) * | 1990-10-18 | 1995-07-04 | Merrell Dow Pharmaceuticals Inc. | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
| CA2053340C (en) * | 1990-10-18 | 2002-04-02 | Timothy P. Burkholder | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
| WO1992015558A1 (fr) * | 1991-03-01 | 1992-09-17 | Zeria Pharmaceutical Co., Ltd. | Derive d'indane et antagoniste de thromboxane le contenant |
| RU2098411C1 (ru) * | 1991-08-02 | 1997-12-10 | Иституто Лусо Фармако д Италия С.п.А. | Производные пиримидина, способ их получения, фармацевтическая композиция на их основе |
| DK0534363T3 (da) * | 1991-09-27 | 1997-09-22 | Merrell Pharma Inc | 2-substituerede indan-2-mercaptoacetylamid-forbindelse med inhiberende virkning på enkephalinase og ACE. |
| KR100276029B1 (ko) * | 1992-02-14 | 2000-12-15 | 슈테펜엘.네스비트 | 아미노아세틸 머캅토아세틸 아미드 유도체 및 이의 제조방법 |
| US5484783A (en) * | 1994-03-24 | 1996-01-16 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives |
| ES2141923T3 (es) * | 1994-03-24 | 2000-04-01 | Merrell Pharma Inc | Uso hipocolesterolemico, antiaterosclerotico e hipotrigliceridemico de derivados aminoacetilmercapto. |
| EP0835106A4 (en) * | 1995-06-30 | 1998-09-30 | Merck & Co Inc | METHOD OF TREATING NEPHROPATHIES USING AN ACE INHIBITOR AND AN A II ANTAGONIST |
| US6060496A (en) | 1995-12-27 | 2000-05-09 | Yoshitomi Pharmaceutical Industires, Ltd. | Prophylaxis and treatment of diabetic complications with 4-[α-hydroxy-2-methyl-5-(1-imidazolyl) benzyl]-3,5-dimethylbenzoic acid |
| DK1216038T3 (da) * | 1999-08-30 | 2005-12-27 | Sanofi Aventis Deutschland | Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser |
| US6149915A (en) | 1999-09-29 | 2000-11-21 | Shiva Biomedical, Llc | Treatment of diabetic nephropathy and microalbuminuria |
| PT1381605E (pt) * | 2001-04-12 | 2005-03-31 | Aventis Pharma Gmbh | Derivados de mercaptoacetilamida um processo para a sua preparacao e utilizacao desses compostos |
| AU2002355419A1 (en) * | 2001-08-06 | 2003-02-24 | Genomed, Llc | Methods and compositions for treating diseases associated with excesses in ace |
-
2002
- 2002-06-28 DE DE2002129180 patent/DE10229180A1/de not_active Ceased
-
2003
- 2003-06-13 CN CNB038153491A patent/CN100366254C/zh not_active Expired - Fee Related
- 2003-06-13 DK DK03740247T patent/DK1519732T3/da active
- 2003-06-13 RU RU2005102087A patent/RU2336080C2/ru not_active IP Right Cessation
- 2003-06-13 AT AT03740247T patent/ATE548040T1/de active
- 2003-06-13 IL IL16593503A patent/IL165935A0/xx unknown
- 2003-06-13 WO PCT/EP2003/006276 patent/WO2004002492A1/en not_active Ceased
- 2003-06-13 MX MXPA04012230A patent/MXPA04012230A/es active IP Right Grant
- 2003-06-13 EP EP20030740247 patent/EP1519732B1/en not_active Expired - Lifetime
- 2003-06-13 SI SI200332139T patent/SI1519732T1/sl unknown
- 2003-06-13 CA CA 2490277 patent/CA2490277C/en not_active Expired - Fee Related
- 2003-06-13 ES ES03740247T patent/ES2383889T3/es not_active Expired - Lifetime
- 2003-06-13 NZ NZ537480A patent/NZ537480A/en not_active IP Right Cessation
- 2003-06-13 HR HRP20041212AA patent/HRP20041212B1/hr not_active IP Right Cessation
- 2003-06-13 OA OA1200400333A patent/OA12871A/en unknown
- 2003-06-13 KR KR1020047021259A patent/KR101072235B1/ko not_active Expired - Fee Related
- 2003-06-13 RS YUP100704 patent/RS52478B/sr unknown
- 2003-06-13 PL PL372992A patent/PL218070B1/pl unknown
- 2003-06-13 AU AU2003280440A patent/AU2003280440B2/en not_active Ceased
- 2003-06-13 BR BR0312250A patent/BR0312250A/pt not_active IP Right Cessation
- 2003-06-13 JP JP2004516596A patent/JP4564354B2/ja not_active Expired - Fee Related
- 2003-06-13 PT PT03740247T patent/PT1519732E/pt unknown
- 2003-06-13 UA UA2005000743A patent/UA82845C2/xx unknown
- 2003-06-20 PE PE2003000623A patent/PE20040582A1/es not_active Application Discontinuation
- 2003-06-23 SV SV2003001560A patent/SV2004001560A/es not_active Application Discontinuation
- 2003-06-24 PA PA8576501A patent/PA8576501A1/es unknown
- 2003-06-26 HN HN2003000193A patent/HN2003000193A/es unknown
- 2003-06-26 AR ARP030102293 patent/AR040343A1/es unknown
- 2003-06-26 TW TW92117352A patent/TWI326215B/zh not_active IP Right Cessation
- 2003-06-26 US US10/607,521 patent/US6930103B2/en not_active Expired - Lifetime
- 2003-06-27 UY UY27869A patent/UY27869A1/es unknown
-
2004
- 2004-11-22 ZA ZA2004/09382A patent/ZA200409382B/en unknown
- 2004-12-08 MA MA27991A patent/MA27281A1/fr unknown
- 2004-12-22 IL IL16593504A patent/IL165935A/en not_active IP Right Cessation
- 2004-12-27 TN TNP2004000262A patent/TNSN04262A1/en unknown
- 2004-12-27 EC ECSP045513 patent/ECSP045513A/es unknown
-
2005
- 2005-01-25 NO NO20050425A patent/NO334811B1/no not_active IP Right Cessation
- 2005-01-28 CR CR7667A patent/CR7667A/es unknown
- 2005-04-01 US US11/096,790 patent/US7514423B2/en not_active Expired - Lifetime
-
2012
- 2012-05-30 CY CY20121100488T patent/CY1112905T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200616940A (en) | Novel hexafluoroisopropanol substituted ether derivatives | |
| AR075104A1 (es) | Compuesto de piperazin-aril-purina, su uso para preparar un medicamento util para el tratamiento del dolor y composicion farmaceutica que lo comprende | |
| MX2010003224A (es) | Derivados de biaril sulfonamida. | |
| GEP20125487B (en) | Organic compounds and their use | |
| UA74391C2 (uk) | Арил- або гетероарилконденсовані імідазоли як антизапальні і анальгетичні агенти | |
| MX2009003410A (es) | Fosfoindoles enantiomericamente puros como inhibidores de vih. | |
| MX2009010567A (es) | Derivados de imidazolidinona. | |
| CO5601011A2 (es) | Derivados de 3-ciclil-5-(anillo de 5 miembros que contiene nitrogeno) metil-oxazolidinona y su uso como agentes antibacterianos | |
| CO6270228A2 (es) | Derivados de quinazilinona 6-, 7-, u 8 -sustituidos y composiciones que los comprenden y metodos para usar los mismos | |
| NZ594230A (en) | Inhibitors of beta-secretase | |
| MX2009010218A (es) | Derivados de aza-piridopirimidinona. | |
| TW200800970A (en) | Novel cycloalkane carboxamides | |
| MX2009005048A (es) | Nuevo proceso para la preparacion de derivados de 2-imino-tiazolidin-4-ona. | |
| MX2009003927A (es) | Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes. | |
| AR041395A1 (es) | Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla | |
| WO2008087611A3 (en) | Pyrrolidine- and piperidine- bis-amide derivatives | |
| NO20090270L (no) | Cinnamoyl-piperazinederivater og deres anvendelse som PAR-I-antagonister | |
| TW200720270A (en) | Novel cyclic amines | |
| EA200970705A1 (ru) | Новые фармацевтические композиции | |
| AR074583A1 (es) | 4-azetidinil-1-heteroaril-ciclohexanol antagonistas del ccr2 | |
| GEP20146063B (en) | Solid pharmaceutical composition | |
| AR076310A1 (es) | 4-azetidinil-1-heteroaril ciclohexanos sustituidos antagonistas de ccr2,composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos en el tratamiento de diabetes,obesidad y otras enfermedades. | |
| TN2011000265A1 (en) | Rifamycin derivatives | |
| DE602005019316D1 (en) | Aromatische etherderivate als thrombin-hemmer | |
| AR056321A1 (es) | COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |